Liquidia Corporation (NASDAQ:LQDA) Stock Has Consensus Price Target of $98.08

Shares of Liquidia Corporation (NASDAQ:LQDA) have earned an average rating of “Hold” from the eleven analysts that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $98.08.

LQDA has been the topic of several research analyst reports. Wells Fargo & Company raised their price objective on shares of Liquidia from $62.00 to $108.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th. Wall Street Zen raised shares of Liquidia from a “hold” rating to a “buy” rating in a report on Sunday, September 20th. Oppenheimer set a $75.00 price target on shares of Liquidia in a research report on Friday, June 5th. Needham & Company LLC raised their price target on shares of Liquidia from $70.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Finally, Lifesci Capital downgraded shares of Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 price objective on the stock. in a report on Wednesday, August 12th.

Liquidia Stock Performance

LQDA opened at $30.26 on Monday. The firm has a market capitalization of $2.71 billion, a P/E ratio of 22.09 and a beta of 0.53. The stock’s 50 day moving average price is $74.00 and its two-hundred day moving average price is $62.32. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. Liquidia has a 12-month low of $21.35 and a 12-month high of $93.61.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The business had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. During the same period in the prior year, the firm earned ($0.49) earnings per share. The business’s quarterly revenue was up 1842.1% on a year-over-year basis. On average, equities analysts forecast that Liquidia will post 2.57 earnings per share for the current year.

Insiders Place Their Bets

In other Liquidia news, CAO Dana Boyle sold 1,600 shares of the company’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $87.53, for a total value of $140,048.00. Following the completion of the transaction, the chief accounting officer owned 167,919 shares of the company’s stock, valued at $14,697,950.07. This represents a 0.94% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Rajeev Saggar sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $74.06, for a total value of $3,703,000.00. Following the completion of the transaction, the insider directly owned 142,265 shares of the company’s stock, valued at approximately $10,536,145.90. This trade represents a 26.01% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 597,519 shares of company stock valued at $46,091,764 in the last quarter. 25.60% of the stock is currently owned by insiders.

Institutional Trading of Liquidia

A number of institutional investors and hedge funds have recently modified their holdings of LQDA. Globeflex Capital L P bought a new position in Liquidia in the second quarter worth $175,000. Nykredit A S acquired a new stake in Liquidia during the second quarter worth $177,000. Hurley Capital LLC increased its holdings in Liquidia by 140.7% in the 4th quarter. Hurley Capital LLC now owns 5,200 shares of the company’s stock valued at $179,000 after buying an additional 3,040 shares during the period. PNC Financial Services Group Inc. increased its holdings in Liquidia by 7.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 6,304 shares of the company’s stock valued at $217,000 after buying an additional 422 shares during the period. Finally, Apollon Wealth Management LLC acquired a new position in shares of Liquidia in the 1st quarter valued at $247,000. 64.54% of the stock is currently owned by institutional investors.

Key Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA adoption is reportedly generating meaningful revenue, cash flow and profitability while the product remains in the early stages of its growth cycle. This provides Liquidia with an operating base to fund additional expansion. Liquidia: Bullish On Their Growth Potential Despite YUTREPIA’s Legal Tail Risk
• Neutral Sentiment: Analyst commentary continues to point to YUTREPIA-driven growth, while comparing Liquidia with Alkermes and its more diversified product portfolio. The comparison highlights both Liquidia’s growth opportunity and its greater concentration risk. LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?
• Neutral Sentiment: Trading in LQDA was repeatedly paused for news pending and volatility-related LULD restrictions, reflecting unusually intense price movement and uncertainty around the court announcement.
• Negative Sentiment: A Delaware federal judge ruled that two claims of United Therapeutics’ ’327 patent are valid and infringed by Liquidia’s YUTREPIA. Although four other asserted claims were found invalid, the ruling creates significant legal and commercial risk. Liquidia Provides Update on Hatch-Waxman Litigation Tied to ’327 Patent
• Negative Sentiment: Potential remedies include removing the PH-ILD indication from YUTREPIA’s label or imposing broader restrictions, including an injunction that could limit product availability. Liquidia plans to appeal and seek a label modification, but the financial impact remains uncertain. Liquidia slumps after US court rules for United Therapeutics in patent fight

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).